Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 1/2 2Phase 2/3 1

Status

Unknown 2Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Recurrence 6Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Locally Advanced Rectal Cancer 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Rectal Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Hyperthermia 2Chondrosarcoma 2Carcinoma, Transitional Cell 2

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT07277777 2026-01-06

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

Jinan Military General Hospital

Phase 2 Not yet recruiting
90 enrolled

Neoplasms, Recurrence

NCT04681131 2025-09-25

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

BioAtla, Inc.

Phase 2 Completed
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07142200 2025-08-26

DECIDING

RenJi Hospital

Phase 2 Not yet recruiting
45 enrolled
Tumor-Agnostic

Neoplasms

NCT04673942 2024-10-26

BETA-PRIME

EpicentRx, Inc.

Phase 2 Recruiting
140 enrolled
Sarcoma

Adenoviridae Infections, Chondrosarcoma, Neoplasms, Sarcoma

NCT06047860 2023-09-21

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT05790447 2023-03-30

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡